Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1979 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ORIGINAL ARTICLE Table of Contents   
Year : 2011  |  Volume : 22  |  Issue : 3  |  Page : 456-463
Prevalence of anemia in predialysis chronic kidney disease patients

1 Saudi Center for Organ Transplantation, Riyadh, Saudi Arabia
2 Kanoo Kidney Center, Dammam, Saudi Arabia
3 Alnoor Specialist Hospital, Makkah, Saudi Arabia
4 King Fahd Hospital, Jeddah, Saudi Arabia
5 King Fahd Hospital, Al Baha, Saudi Arabia
6 King Fahd Hospital, Gizan, Saudi Arabia
7 King Fahd Hospital, Hofuf, Saudi Arabia
8 Assir Central Hospital, Saudi Arabia
9 King Fahd Specialist Hospital, Al Qassim, Saudi Arabia
10 King Fahad Hospital, Madina, Saudi Arabia
11 Buraida Central Hospital, Saudi Arabia
12 King Khaled Hospital, Hail, Saudi Arabia

Correspondence Address:
FAM Shaheen
Saudi Center for Organ Transplantation, P.O. Box 27049, Riyadh
Saudi Arabia
Login to access the Email id

PMID: 21566300

Rights and Permissions

To evaluate the prevalence of anemia in a large cohort that comprises patients in different stages of chronic kidney disease (CKD) in the kingdom of Saudi Arabia (KSA), we conducted a multi-center cross-sectional study of a cohort of CKD patients who have not started dialysis. The study patients were recruited from the nephrology clinics in 11 different medical centers distributed all over the regions of the KSA. For the estimated glomerular filtration rate (GFR), we used the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. There were 250 study patients who fulfilled the criteria for the study. The patients were stratified according to their GFR as follows: stage 1: 19 patients, stage 2: 35 patients, stage 3: 67 patients, stage 4: 68 patients, and stage 5: 61 patients. The composite of proteinuria and abnormal imaging in stages 1 and 2 was satisfied in 100% of the cases. The prevalence of anemia was elevated for the hemoglobin levels below 12 g/dL (the level at which the evaluation of anemia in CKD should be initiated) in the different stages of CKD, that is, 42%, 33%, 48%, 71%, and 82% in the stages from 1 to 5, respectively. The prevalence was also elevated for the hemoglobin levels below 11 g/dL (the minimum hemoglobin level at which therapy should be initiated with erythropoietin), that is, 21%, 17%, 31%, 49%, and 72%, respectively for stages from 1 to 5. In conclusion, we found a large prevalence of anemia among the CKD population in Saudi Arabia, and the burden of patients who require treatment with erythropoietin is considerably large. However, the response to therapy will not require large doses according to the availability of long-acting erythropoiesis stimulating agents, which will render the therapy more convenient and less expensive.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded1243    
    Comments [Add]    
    Cited by others 2    

Recommend this journal